Antithrombotic and Lipid Lowering Therapy is Associated With Improved Survival After Vascular Surgery: A Population

Martin Altreuther1, Arne Seternes2, Turi Saltnes3

  • 1Section of Vascular Surgery, Department of Surgery, Trondheim University Hospital, St Olavs Hospital, Trondheim, Norway; Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; Norwegian Registry for Vascular surgery (NORKAR), Department of Medical Quality Registries, St Olavs hospital, Trondheim University Hospital, Trondheim, Norway.

Insights

Combined lipid-lowering drugs and antiplatelet/anticoagulant therapy significantly improved long-term survival after vascular surgery. Patients with lower extremity arterial disease (LEAD) saw the greatest survival benefit from these recommended medications.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Public Health

Background:

  • Vascular surgery aims to improve outcomes for conditions like carotid stenosis, abdominal aortic aneurysm (AAA), and atherosclerotic lower extremity arterial disease (LEAD).
  • Optimizing post-operative medical management, including pharmacotherapy, is crucial for long-term patient survival.

Purpose of the Study:

  • To investigate the association between combined lipid-lowering drugs and antiplatelet or anticoagulation therapy and long-term survival following vascular surgery.
  • To assess the impact of recommended medications on survival across different vascular conditions and patient demographics.

Main Methods:

  • Retrospective cohort study of patients undergoing vascular surgery in Norway (2015-2019).
  • Analysis included patients with carotid stenosis, AAA, and LEAD discharged alive.
  • Survival was assessed using Kaplan-Meier analysis and multivariable Cox regression, stratified by treatment and medication adherence.

Main Results:

  • Patients receiving recommended medications (lipid-lowering drugs plus antiplatelets or anticoagulants) upon discharge showed superior survival across all treatment groups.
  • The greatest survival difference was observed in patients with LEAD, with mean survival periods of 4.33 years vs. 3.7 years.
  • Cox regression revealed significantly lower mortality rates for patients on recommended medications for LEAD (HR 0.58) and AAA (HR 0.57).

Conclusions:

  • Recommended medications are associated with improved survival in both sexes and across all vascular surgery treatment groups.
  • The survival benefit was statistically significant for patients with LEAD and AAA, with LEAD patients experiencing the most substantial improvement.
  • Adherence to recommended secondary prophylaxis, particularly for patients with LEAD, is strongly emphasized for enhanced long-term outcomes.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
12
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
192